{"id":"paclitaxel-x","safety":{"commonSideEffects":[{"rate":"75–90","effect":"Neutropenia"},{"rate":"52–87","effect":"Peripheral neuropathy"},{"rate":"60","effect":"Myalgia/arthralgia"},{"rate":"80","effect":"Alopecia"},{"rate":"52","effect":"Nausea/vomiting"},{"rate":"43","effect":"Diarrhea"},{"rate":"2–12","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL428647","moleculeType":"Small molecule","molecularWeight":"853.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel is a microtubule-stabilizing agent that binds to the β-tubulin subunit of microtubules, preventing their normal dynamic instability. This stabilization disrupts mitotic spindle formation and cell division, leading to G2/M phase arrest and triggering apoptosis in rapidly dividing cancer cells. It is effective against a broad range of solid tumors.","oneSentence":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:24.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic carcinoma of the ovary"},{"name":"Breast cancer (metastatic and adjuvant)"},{"name":"Non-small cell lung cancer"},{"name":"Kaposi's sarcoma"},{"name":"Gastric adenocarcinoma"}]},"trialDetails":[{"nctId":"NCT04090398","phase":"PHASE2","title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone","enrollment":70},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT05019716","phase":"PHASE1, PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":"Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma","enrollment":36},{"nctId":"NCT04095364","phase":"PHASE3","title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2019-09-20","conditions":"Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma","enrollment":450},{"nctId":"NCT06708455","phase":"PHASE2","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Rapa Therapeutics LLC","startDate":"2027-03-01","conditions":"Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc","enrollment":65},{"nctId":"NCT01374620","phase":"PHASE1","title":"Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2011-07-13","conditions":"Cancer","enrollment":28},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":327},{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":"Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8","enrollment":17},{"nctId":"NCT02705196","phase":"PHASE1, PHASE2","title":"LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Lokon Pharma AB","startDate":"2016-11","conditions":"Pancreatic Cancer","enrollment":51},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT07102940","phase":"PHASE2","title":"Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2026-05-01","conditions":"Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":50},{"nctId":"NCT06731907","phase":"PHASE2","title":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-30","conditions":"Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT05415709","phase":"EARLY_PHASE1","title":"Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2022-06-13","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":45},{"nctId":"NCT04297605","phase":"PHASE1","title":"Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2020-05-15","conditions":"Non-small Cell Lung Cancer","enrollment":28},{"nctId":"NCT01081951","phase":"PHASE2","title":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2010-02-04","conditions":"Ovarian Cancer","enrollment":162},{"nctId":"NCT01796197","phase":"PHASE2","title":"Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-08","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07372079","phase":"PHASE2","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-05","conditions":"Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":40},{"nctId":"NCT05500092","phase":"PHASE2","title":"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2023-01-25","conditions":"Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","enrollment":17},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT03245892","phase":"PHASE1","title":"A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-04","conditions":"High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":27},{"nctId":"NCT04858009","phase":"PHASE2","title":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-02-15","conditions":"Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":40},{"nctId":"NCT07280377","phase":"PHASE1, PHASE2","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","status":"RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2021-10-27","conditions":"Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic","enrollment":122},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT04373031","phase":"PHASE2","title":"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2020-12-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":12},{"nctId":"NCT04338399","phase":"PHASE3","title":"The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC","status":"COMPLETED","sponsor":"Adlai Nortye Biopharma Co., Ltd.","startDate":"2020-12-12","conditions":"Head and Neck Cancer","enrollment":487},{"nctId":"NCT04821284","phase":"PHASE1, PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":120},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT04877821","phase":"PHASE2","title":"The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-09-15","conditions":"Triple Negative Breast Cancer","enrollment":31},{"nctId":"NCT00861705","phase":"PHASE2","title":"Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-21","conditions":"Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7","enrollment":454},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT04335669","phase":"PHASE3","title":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2019-12-20","conditions":"Breast Cancer, Triple Negative Breast Neoplasms","enrollment":325},{"nctId":"NCT04159142","phase":"PHASE2","title":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2019-11-20","conditions":"Triple Negative Breast Cancer, Nab-paclitaxel","enrollment":414},{"nctId":"NCT04138719","phase":"PHASE2","title":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2019-11-20","conditions":"Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel","enrollment":520},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT01770418","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2013-03","conditions":"Lung Neoplasms","enrollment":32},{"nctId":"NCT02608216","phase":"PHASE1","title":"[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2015-11","conditions":"Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer","enrollment":20},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":"Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8","enrollment":50},{"nctId":"NCT06356688","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Jing","startDate":"2025-04-20","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":30},{"nctId":"NCT06691425","phase":"NA","title":"Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2024-07-19","conditions":"Non-metastasized Unresectable Pancreatic Carcinoma","enrollment":160},{"nctId":"NCT00243867","phase":"PHASE3","title":"Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2005-11","conditions":"Non-Small Cell Lung Cancer","enrollment":518},{"nctId":"NCT05691829","phase":"PHASE2","title":"Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2023-01-24","conditions":"NSCLC Stage IV","enrollment":19},{"nctId":"NCT02730416","phase":"PHASE2","title":"Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer","status":"COMPLETED","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2016-12-12","conditions":"Endometrial Cancer","enrollment":146},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT05605535","phase":"PHASE2","title":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanariaBio Inc.","startDate":"2023-02-07","conditions":"Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms","enrollment":88},{"nctId":"NCT06687876","phase":"PHASE2","title":"Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2025-03-09","conditions":"Oesophageal Adenocarcinoma, Tumor Microenvironment","enrollment":14},{"nctId":"NCT04498117","phase":"PHASE3","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanariaBio Inc.","startDate":"2020-08-25","conditions":"Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer","enrollment":615},{"nctId":"NCT04543071","phase":"PHASE2","title":"Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2020-11-09","conditions":"Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma","enrollment":10},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT07013851","phase":"PHASE2","title":"Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2025-10-01","conditions":"MMRd/MSI-H Stage II-III Endometrial Cancer","enrollment":25},{"nctId":"NCT05136846","phase":"PHASE1","title":"Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2021-12-06","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8","enrollment":28},{"nctId":"NCT05516589","phase":"PHASE2","title":"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT05144698","phase":"PHASE1, PHASE2","title":"RAPA-201 Therapy of Solid Tumors","status":"RECRUITING","sponsor":"Rapa Therapeutics LLC","startDate":"2021-08-01","conditions":"Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer","enrollment":37},{"nctId":"NCT05705687","phase":"NA","title":"Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-05-05","conditions":"Non-Seminomatous Germ Cell Tumor","enrollment":150},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT06190600","phase":"NA","title":"Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Greater Poland Cancer Centre","startDate":"2018-10-11","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT06003075","phase":"PHASE2","title":"Induction Chemo-Nivo in Unresectable Stage III NSCLC","status":"TERMINATED","sponsor":"Ralph G Zinner","startDate":"2023-12-13","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage III","enrollment":1},{"nctId":"NCT06944587","phase":"","title":"A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-12-03","conditions":"Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Pancreatectomy","enrollment":400},{"nctId":"NCT03984214","phase":"PHASE3","title":"Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2019-12-16","conditions":"Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic","enrollment":109},{"nctId":"NCT01779206","phase":"PHASE2, PHASE3","title":"ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-05","conditions":"Breast Cancer","enrollment":4936},{"nctId":"NCT04274426","phase":"PHASE2","title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AGO Research GmbH","startDate":"2021-10-13","conditions":"Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma","enrollment":136},{"nctId":"NCT06502743","phase":"PHASE2","title":"First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-09-12","conditions":"Endometrial Cancer, Recurrent Endometrial Carcinoma, Endometrial Carcinoma","enrollment":92},{"nctId":"NCT02305654","phase":"PHASE3","title":"International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2017-05-12","conditions":"Squamous Cell Carcinoma of the Penis, Usual Type","enrollment":200},{"nctId":"NCT03165955","phase":"PHASE1","title":"A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients","status":"COMPLETED","sponsor":"Health Hope Pharma","startDate":"2017-05-09","conditions":"Breastcancer","enrollment":28},{"nctId":"NCT05498896","phase":"PHASE2","title":"Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2018-12-19","conditions":"Triple Negative Breast Cancer","enrollment":146},{"nctId":"NCT03871036","phase":"PHASE1, PHASE2","title":"Improve Checkpoint-blockade Response in Advanced Urothelial Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2019-05-01","conditions":"Urothelial Carcinoma","enrollment":53},{"nctId":"NCT04460352","phase":"PHASE3","title":"Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2020-11-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":1020},{"nctId":"NCT02214381","phase":"PHASE3","title":"A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2014-07","conditions":"Early Primary Breast Cancer","enrollment":80},{"nctId":"NCT05737303","phase":"PHASE3","title":"Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2023-11-27","conditions":"Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III","enrollment":538},{"nctId":"NCT02891824","phase":"PHASE3","title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2016-09-22","conditions":"Ovarian Cancer","enrollment":614},{"nctId":"NCT04215146","phase":"PHASE2","title":"A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2020-06-10","conditions":"Breast Cancer Metastatic","enrollment":48},{"nctId":"NCT02630823","phase":"PHASE1","title":"MK-3475 Immunotherapy in Endometrial Carcinoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-02-05","conditions":"Endometrial Cancer, Endometrial Carcinoma, Neoplasms, Endometrial","enrollment":10},{"nctId":"NCT02938442","phase":"PHASE1, PHASE2","title":"Vaccination of Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2019-01-25","conditions":"Triple Negative Breast Cancer, Breast Neoplasms","enrollment":16},{"nctId":"NCT05403554","phase":"PHASE1","title":"A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers","status":"RECRUITING","sponsor":"Light Chain Bioscience - Novimmune SA","startDate":"2022-04-29","conditions":"Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer","enrollment":70},{"nctId":"NCT05501665","phase":"PHASE1, PHASE2","title":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2023-05-09","conditions":"Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer","enrollment":25},{"nctId":"NCT06639672","phase":"PHASE2","title":"Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Lei Liu","startDate":"2024-11-01","conditions":"HR+HER2- Breast Cancer","enrollment":60},{"nctId":"NCT05831033","phase":"EARLY_PHASE1","title":"Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-23","conditions":"Solid Tumor","enrollment":16},{"nctId":"NCT06510660","phase":"PHASE2","title":"Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-04-11","conditions":"Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers","enrollment":48},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT04461977","phase":"NA","title":"Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Instituto Brasileiro de Controle do Cancer","startDate":"2020-01-30","conditions":"Peripheral Neuropathy Due to Chemotherapy","enrollment":60},{"nctId":"NCT06432075","phase":"EARLY_PHASE1","title":"Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-06-01","conditions":"Advanced Gastric Cancer","enrollment":20},{"nctId":"NCT06391008","phase":"PHASE2","title":"Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-04-30","conditions":"Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer","enrollment":44},{"nctId":"NCT06371807","phase":"PHASE2","title":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Fundacao Champalimaud","startDate":"2024-07","conditions":"Early Breast Cancer, Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT03281954","phase":"PHASE3","title":"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2017-12-19","conditions":"Triple Negative Breast Cancer","enrollment":1550},{"nctId":"NCT04561739","phase":"NA","title":"Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2021-02-01","conditions":"De Novo Stenosis, Coronary Artery Disease","enrollment":2272},{"nctId":"NCT02619448","phase":"EARLY_PHASE1","title":"Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC","status":"RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer","enrollment":12},{"nctId":"NCT03189446","phase":"PHASE2","title":"Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2017-10-02","conditions":"Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer","enrollment":39},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT05562089","phase":"NA","title":"Prevail Drug Balloon Study","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2022-04-29","conditions":"Myocardial Infarction, Drug-Coated Balloon","enrollment":50},{"nctId":"NCT05983276","phase":"PHASE2","title":"Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer","status":"RECRUITING","sponsor":"Loyola University","startDate":"2023-11-16","conditions":"Ovarian Cancer","enrollment":40},{"nctId":"NCT01691625","phase":"NA","title":"Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Carcinoma","enrollment":50},{"nctId":"NCT03283761","phase":"PHASE2","title":"FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Al B. Benson, III, MD","startDate":"2017-09-21","conditions":"Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1352,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAXOL®"],"phase":"phase_3","status":"active","brandName":"Paclitaxel (X)","genericName":"Paclitaxel (X)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel is used to treat various types of cancer, including non-small cell lung cancer, endometrial cancer, and recurrent epithelial ovarian, fallopian, or peritoneal carcinoma. It is often administered in combination with other medications, such as carboplatin, as part of clinical trials to evaluate its safety and efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}